Instructions for Celecoxib-Vial capsules
English product name
Celecoxib-Vial
Release Form
caps. 200 mg: 10, 20, 30, 40, 50, 60, 70, 80, 90 or 100 pcs.
Description Celecoxib-Vial
The capsules are solid, gelatinous, size 1, the lid is blue in colour, and the body is almost white; the contents of the capsules are white or almost white in colour.
1 cap.
tselekoxib 200 mg
Adjuvants: Anhydrous lactose - 86.26 mg, talc - 14 mg, sodium croscarmellose - 3.87 mg, silica colloidal - 3.87 mg, sodium lauryl sulfate - 2 mg.
The capsule lid contains: 0.195% diamond blue dye, 2.357% titanium dixide, 0.8% methylparahydroxybenzoate, 0.2% propyl parahydroxyenzoate, 0.1% sodium lauryl sulfate, and up to 100% gelatin.
The capsule body contains: titanium dioxide - 3%, matilparhydroxybenzoate - 0.8%, propyl parhydroxybenzoate - 0.2%, sodium lauryl sulfate - 0.1%, gelatin - up to 100%.
ATC codes
M01AH01 Celecoxib
Active substance
tselekoxib
Pharmaco-therapeutic group Celecoxib-Vial
NSAIDs
Pharmacological effect
NAPS. It is a selective inhibitor of COX-2, thus blocking the formation of inflammatory prostanoids.
In therapeutic concentrations in humans, celecoxib does not inhibit COX-1, hence does not affect prostanoids synthesized by COX-1 activation.
Criteria for defining specificity in relation to COX-2 include the absence of side effects due to COX-1, especially ulcerative lesions of the stomach and duodenum, serious complications from upper gastrointestinal tract (bleeding, perforations, sawdust obstruction) and the absence of inhibition of COX-2-dependent aggregation activity of platelets.
Testimony Celecoxib-Vial
Symptomatic treatment of pain syndrome and inflammation in osteoarthritis and rheumatoid arthritis.
Method of use, course and dosage Celecoxib-Vial
For adults, the dose is 200 mg/day in 1-2 doses, and if necessary, 200 mg twice daily.
Elderly patients with a body weight of less than 50 kg or moderate liver failure should begin treatment with the minimum recommended dose.
There is no clinical experience with celecoxib in patients with severe liver or kidney disorders.
- Nosology (ICD codes)
- M05
- Seropositive rheumatoid arthritis
- M15
- Polyarthrosis
- M19.9
- Arthrosis unspecified
- M25.5
- Joint pain
